Stephen Danko is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations related to insulin-like growth factors. With a total of 2 patents, his work has the potential to impact medical treatments and therapies.

Latest Patents

Danko's latest patents include innovative pharmaceutical formulations for the IGF/IGFBP complex. These formulations are designed without added osmolyte salts and include bulking agents and optional buffer salts. Additionally, he has developed lyophilized formulations for the IGF/IGFBP complex. Another significant invention relates to variants of native insulin-like growth factor binding protein 3 (IGFBP-3). These variants are modified to resist hydrolysis and include alterations to the nuclear localization signal (NLS). Furthermore, his work encompasses amino-terminally extended IGFBP-3s, which feature various N-terminal extensions, including peptide and nucleotide binding domains.

Career Highlights

Stephen Danko is currently associated with Celtrix Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, particularly in the area of growth factor therapies.

Collaborations

Danko has collaborated with notable colleagues such as David Passmore and Yasushi Ogawa, contributing to a dynamic research environment that fosters innovation.

Conclusion

Stephen Danko's contributions to pharmaceutical formulations and growth factor research highlight his role as a significant inventor in the field. His patents reflect a commitment to advancing medical science and improving therapeutic options.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]